Organigram (OGI) Competitors

C$1.89 0.00 (0.00%)

As of 03:59 PM Eastern

OGI vs. CMED, WEED, EMC, ICC, and LEAF

Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include CanniMed Therapeutics (CMED), Canopy Growth (WEED), Emblem (EMC), ICC Labs (ICC), and Leaf Mobile (LEAF). These companies are all part of the "cannabis" industry.

How does Organigram compare to CanniMed Therapeutics?

Organigram (TSE:OGI) and CanniMed Therapeutics (TSE:CMED) are both small-cap cannabis companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

: CanniMed Therapeutics has lower revenue, but higher earnings than Organigram.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Organigram C$279.99M 0.95 -C$57.23M C$0.15 12.27
CanniMed Therapeutics N/A N/A N/A N/A N/A
: In the previous week, Organigram's average media sentiment score of 0.00 equaled CanniMed Therapeutics'average media sentiment score.
Company Overall Sentiment
Organigram Neutral
CanniMed Therapeutics Neutral
: Organigram has a net margin of 6.49% compared to CanniMed Therapeutics' net margin of 0.00%. Organigram's return on equity of 4.86% beat CanniMed Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Organigram 6.49% 4.86% -5.56%
CanniMed Therapeutics N/A N/A N/A
: 4.0% of Organigram shares are owned by institutional investors. 31.3% of Organigram shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
: Organigram presently has a consensus price target of C$3.13, suggesting a potential upside of 65.34%. Given Organigram's stronger consensus rating and higher probable upside, equities research analysts clearly believe Organigram is more favorable than CanniMed Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organigram
0 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
3.00
CanniMed Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$279.99M	0.95	-C$57.23M	C$0.15	12.27
CanniMed Therapeutics	N/A	N/A	N/A	N/A	N/A

Company	Overall Sentiment
Organigram	Neutral
CanniMed Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Organigram	6.49%	4.86%	-5.56%
CanniMed Therapeutics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
CanniMed Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Organigram beats CanniMed Therapeutics on 8 of the 9 factors compared between the two stocks.

How does Organigram compare to Canopy Growth?

Organigram (TSE:OGI) and Canopy Growth (TSE:WEED) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

: Organigram currently has a consensus price target of C$3.13, suggesting a potential upside of 65.34%. Canopy Growth has a consensus price target of C$1.97, suggesting a potential upside of 31.11%. Given Organigram's stronger consensus rating and higher possible upside, analysts clearly believe Organigram is more favorable than Canopy Growth.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organigram
0 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
3.00
Canopy Growth
0 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.67
: Organigram has a beta of 1.535528, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 1.605535, indicating that its share price is 61% more volatile than the S&P 500.
: Organigram has higher revenue and earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Organigram C$279.99M 0.95 -C$57.23M C$0.15 12.27
Canopy Growth C$278.39M 2.28 -C$1.05B -C$1.86 N/A
: In the previous week, Canopy Growth had 1 more articles in the media than Organigram. MarketBeat recorded 1 mentions for Canopy Growth and 0 mentions for Organigram. Canopy Growth's average media sentiment score of 0.98 beat Organigram's score of 0.00 indicating that Canopy Growth is being referred to more favorably in the news media.
Company Overall Sentiment
Organigram Neutral
Canopy Growth Positive
: Organigram has a net margin of 6.49% compared to Canopy Growth's net margin of -117.31%. Organigram's return on equity of 4.86% beat Canopy Growth's return on equity.
Company Net Margins Return on Equity Return on Assets
Organigram 6.49% 4.86% -5.56%
Canopy Growth -117.31% -52.88% -3.83%
: 4.0% of Organigram shares are held by institutional investors. Comparatively, 3.6% of Canopy Growth shares are held by institutional investors. 31.3% of Organigram shares are held by insiders. Comparatively, 0.2% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organigram	C$279.99M	0.95	-C$57.23M	C$0.15	12.27
Canopy Growth	C$278.39M	2.28	-C$1.05B	-C$1.86	N/A

Company	Overall Sentiment
Organigram	Neutral
Canopy Growth	Positive

Company	Net Margins	Return on Equity	Return on Assets
Organigram	6.49%	4.86%	-5.56%
Canopy Growth	-117.31%	-52.88%	-3.83%

Summary

Organigram beats Canopy Growth on 10 of the 15 factors compared between the two stocks.

How does Organigram compare to Emblem?

Emblem (CVE:EMC) and Organigram (TSE:OGI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

: Organigram has a consensus price target of C$3.13, suggesting a potential upside of 65.34%. Given Organigram's stronger consensus rating and higher possible upside, analysts clearly believe Organigram is more favorable than Emblem.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Emblem
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Organigram
0 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
3.00
: Emblem has higher earnings, but lower revenue than Organigram. Emblem is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Emblem $5.71M 43.02 -$24.81M -$0.19 N/A
Organigram C$279.99M 0.95 -C$57.23M C$0.15 12.27
: In the previous week, Emblem's average media sentiment score of 0.00 equaled Organigram'saverage media sentiment score.
Company Overall Sentiment
Emblem Neutral
Organigram Neutral
: Organigram has a net margin of 6.49% compared to Emblem's net margin of 0.00%. Organigram's return on equity of 4.86% beat Emblem's return on equity.
Company Net Margins Return on Equity Return on Assets
Emblem N/A N/A N/A
Organigram 6.49% 4.86% -5.56%
: 4.0% of Organigram shares are held by institutional investors. 31.3% of Organigram shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Emblem	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Emblem	$5.71M	43.02	-$24.81M	-$0.19	N/A
Organigram	C$279.99M	0.95	-C$57.23M	C$0.15	12.27

Company	Overall Sentiment
Emblem	Neutral
Organigram	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Emblem	N/A	N/A	N/A
Organigram	6.49%	4.86%	-5.56%

Summary

Organigram beats Emblem on 10 of the 13 factors compared between the two stocks.

How does Organigram compare to ICC Labs?

ICC Labs (CVE:ICC) and Organigram (TSE:OGI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

: In the previous week, ICC Labs' average media sentiment score of 0.00 equaled Organigram'saverage media sentiment score.
Company Overall Sentiment
ICC Labs Neutral
Organigram Neutral
: 4.0% of Organigram shares are owned by institutional investors. 31.3% of Organigram shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Organigram has a net margin of 6.49% compared to ICC Labs' net margin of 0.00%. Organigram's return on equity of 4.86% beat ICC Labs' return on equity.
Company Net Margins Return on Equity Return on Assets
ICC Labs N/A N/A N/A
Organigram 6.49% 4.86% -5.56%
: ICC Labs has higher earnings, but lower revenue than Organigram. Organigram is trading at a lower price-to-earnings ratio than ICC Labs, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ICC Labs C$533.68K 419.04 C$2.35M C$0.02 95.29
Organigram C$279.99M 0.95 -C$57.23M C$0.15 12.27
: Organigram has a consensus price target of C$3.13, suggesting a potential upside of 65.34%. Given Organigram's stronger consensus rating and higher probable upside, analysts clearly believe Organigram is more favorable than ICC Labs.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ICC Labs
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Organigram
0 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
3.00

Company	Overall Sentiment
ICC Labs	Neutral
Organigram	Neutral

Company	Net Margins	Return on Equity	Return on Assets
ICC Labs	N/A	N/A	N/A
Organigram	6.49%	4.86%	-5.56%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ICC Labs	C$533.68K	419.04	C$2.35M	C$0.02	95.29
Organigram	C$279.99M	0.95	-C$57.23M	C$0.15	12.27

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ICC Labs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Organigram beats ICC Labs on 9 of the 13 factors compared between the two stocks.

How does Organigram compare to Leaf Mobile?

Leaf Mobile (TSE:LEAF) and Organigram (TSE:OGI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

: In the previous week, Leaf Mobile's average media sentiment score of 0.00 equaled Organigram'saverage media sentiment score.
Company Overall Sentiment
Leaf Mobile Neutral
Organigram Neutral
: 4.0% of Organigram shares are owned by institutional investors. 31.3% of Organigram shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Organigram has a net margin of 6.49% compared to Leaf Mobile's net margin of 0.00%. Organigram's return on equity of 4.86% beat Leaf Mobile's return on equity.
Company Net Margins Return on Equity Return on Assets
Leaf Mobile N/A N/A N/A
Organigram 6.49% 4.86% -5.56%
: Leaf Mobile has higher earnings, but lower revenue than Organigram. Leaf Mobile is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Leaf Mobile C$83.74M 0.00 C$3.37M C$0.04 N/A
Organigram C$279.99M 0.95 -C$57.23M C$0.15 12.27
: Organigram has a consensus price target of C$3.13, suggesting a potential upside of 65.34%. Given Organigram's stronger consensus rating and higher probable upside, analysts clearly believe Organigram is more favorable than Leaf Mobile.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Leaf Mobile
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Organigram
0 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
3.00

Company	Overall Sentiment
Leaf Mobile	Neutral
Organigram	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Leaf Mobile	N/A	N/A	N/A
Organigram	6.49%	4.86%	-5.56%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Leaf Mobile	C$83.74M	0.00	C$3.37M	C$0.04	N/A
Organigram	C$279.99M	0.95	-C$57.23M	C$0.15	12.27

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Leaf Mobile	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Organigram	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Organigram beats Leaf Mobile on 9 of the 12 factors compared between the two stocks.

Get Organigram News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OGI vs. The Competition

Export

Metric	Organigram	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$265.80M	C$1.62B	C$6.25B	C$11.72B
Dividend Yield	N/A	2.97%	2.74%	6.22%
P/E Ratio	12.27	4.18	24.91	23.83
Price / Sales	0.95	1,488.53	504.56	13.46
Price / Cash	3.85	10.37	43.30	82.69
Price / Book	0.69	10.72	9.67	4.48
Net Income	-C$57.23M	C$21.15B	C$3.55B	C$300.68M
7 Day Performance	-1.56%	-1.16%	1.70%	0.12%
1 Month Performance	-1.56%	0.17%	5.62%	2.88%
1 Year Performance	21.94%	24.19%	34.42%	57.78%

Organigram Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OGI Organigram	3.5773 of 5 stars	C$1.89 flat	C$3.13 +65.3%	N/A	C$265.80M	C$279.99M	12.27	987
CMED CanniMed Therapeutics	N/A	N/A	N/A	N/A	C$668.44M	N/A	N/A	147,000
WEED Canopy Growth	2.8778 of 5 stars	C$1.58 -3.7%	C$1.97 +24.5%	N/A	C$668.05M	C$278.39M	N/A	2,700
EMC Emblem	N/A	$1.88 +1.6%	N/A	N/A	$245.45M	$5.71M	N/A	N/A
ICC ICC Labs	N/A	C$1.62 -5.8%	N/A	N/A	C$223.64M	C$533.68K	95.29	N/A	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:OGI) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organigram (OGI) Competitors

OGI vs. CMED, WEED, EMC, ICC, and LEAF

How does Organigram compare to CanniMed Therapeutics?

Summary

How does Organigram compare to Canopy Growth?

Summary

How does Organigram compare to Emblem?

Summary

How does Organigram compare to ICC Labs?

Summary

How does Organigram compare to Leaf Mobile?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGI vs. The Competition

Organigram Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organigram (OGI) Competitors

OGI vs. CMED, WEED, EMC, ICC, and LEAF

How does Organigram compare to CanniMed Therapeutics?

Summary

How does Organigram compare to Canopy Growth?

Summary

How does Organigram compare to Emblem?

Summary

How does Organigram compare to ICC Labs?

Summary

How does Organigram compare to Leaf Mobile?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGI vs. The Competition

Organigram Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools